NCT00620230 is a Phase 1 clinical trial of NVP-VAK694 in Allergic Rhinitis, sponsored by Novartis.

Who is sponsoring NCT00620230?

NCT00620230 is sponsored by Novartis.

What drugs are being tested in NCT00620230?

Interventions in NCT00620230: NVP-VAK694, NVP-VAK694.

What condition does NCT00620230 study?

NCT00620230 studies Allergic Rhinitis.

Is NCT00620230 still recruiting?

NCT00620230 is currently completed. Last updated 24 September 2010.

Last reviewed 2010-09-24 · How we verify

NCT00620230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Profile and Pharmacodynamic Effect of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

Completed Phase 1 Last updated 24 September 2010

What this trial tests

Phase 1 trial testing NVP-VAK694 in Allergic Rhinitis in 46 participants. Completed in 1 April 2008.

Timeline

1 October 2007

Primary endpoint
1 April 2008

1 April 2008

Quick facts

Lead sponsor	Novartis
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Enrollment	46
Start date	1 October 2007
Primary completion	1 April 2008
Estimated completion	1 April 2008
Sites	1 location across United States

Drugs / interventions tested

NVP-VAK694 — full drug profile →
NVP-VAK694 — full drug profile →

Conditions studied

Allergic Rhinitis — all drugs for Allergic Rhinitis →

Sponsor

Novartis — full company profile →

Who can join

Adults 18 to 60, any sex, with Allergic Rhinitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Routine safety observations and pharmacokinetic measurements
Time frame: throughout the study

Sponsor's own description

This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma.
Nur Husna SM, Md Shukri N, Mohd Ashari NS, Wong KK. · · 2022 · cited 65× · PMID 35663523 · DOI 10.7717/peerj.13444

Verify or expand the search:

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting

Other Novartis trials

Trials by the same sponsor.

NCT06595069 — A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients · completed
NCT06632730 — Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain · completed
NCT06395909 — A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis · completed
NCT06516029 — Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Ascimini · completed
NCT06644638 — Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple S · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00620230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis
Last refreshed: 24 September 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00620230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing